An ASK1 deficiency or ASK1 inhibitor attenuated the sensitivity of experimental autoimmune encephalomyelitis, an animal model of MS, suggesting that ASK1 is a potential therapeutic target for the treatment of MS. This evidence concerns the gene MAP3K5 and experimental autoimmune encephalomyelitis.